Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 2

Interventions

Cyclophosphamide 222pembrolizumab 201Carboplatin 173Cisplatin 168Gemcitabine 167Paclitaxel 155Docetaxel 140Bevacizumab 138Rituximab 137Radiotherapy 137Nivolumab 126Dexamethasone 126Capecitabine 103fludarabine 102Pemetrexed 92fludarabine phosphate 91Fluorouracil 91Doxorubicin 85Oxaliplatin 79Etoposide 77Cytarabine 77Bortezomib 76Erlotinib Hydrochloride 74Leucovorin 72Filgrastim 68Lenalidomide 67Calcium Dobesilate 66Irinotecan 65atezolizumab 63Radiation 61

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Has results × vadastuximab talirine × Clear all
NCT02614560 2019-01-09

A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients

Seagen Inc.

Phase 1/2 Terminated
14 enrolled 16 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02785900 2018-12-12

CASCADE

Seagen Inc.

Phase 3 Terminated
240 enrolled 20 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡